osimertinib
astrazeneca
['sclc', 'nsclc', 'osimertinib']
great presentation by on a phase ii trial for neoadjuvant osimertinib of stages i-iii egfrm nsclc. despite 15% of mpr and all patients the study did not meet its primary ep. should we be looking for combinations in this setting? #asco23
Husband, Father.
Medical Oncologist and Researcher focused in Thoracic Oncology.
Views are my own.